Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2012

View Archived Issues

Novel biomarker presented by the National Institute on Drug Abuse

CSL-362 shows efficacy in AML animal models

German researchers patent novel anti-PRL-R antibody

Novel protein kinase B inhibitors presented by German researchers

Merck KGaA discloses new TBK1 and IKK-epsilon inhibitors

Bayer Intellectual Property presents novel CDK inhibitors

Janssen Pharmaceutica prepares novel glucagon receptor antagonists

The University of Dundee synthesizes new D4/5-HT1A receptor ligands

Researchers develop a novel hTSLP+/- xenograft model to study B-ALL

Investigators report results of clinical study testing Wilms tumor protein analogue peptide vaccine

TLS obtains IND clearance for clinical trial protocol based on crowdsourcing

Abexinostat monotherapy shows significant clinical activity in phase II trials

Novo Nordisk provides update on three clinical development programs

Actelion's novel antibiotic advances into phase III development

Novel mRNA-based influenza vaccine presented by CureVac

Genentech unveils an indicator of LRRK2 kinase activity and novel LRRK2 inhibitor

NPS gains FDA approval for Gattex in treatment of adult short bowel syndrome

New administration route approved for bortezomib in Japan

Exjade approved in Europe for iron overload in patients with thalassemia

Celgene presents promising in vitro results for CC-122

FDA approves Varizig for reducing the severity of chickenpox in individuals at high risk

FDA approves Alexza's Adasuve for acute treatment of agitation

Application filed for use of OneDuro Patch as once-daily treatment of chronic pain in Japan

EMA accepts MAA for aripiprazole depot formulation

FDA expands approval of Tamiflu

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.